Feb 12, 2024
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Oct 29, 2020
Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children >=2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)
Jul 30, 2020
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
Jun 12, 2020
CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit
Jun 08, 2020
CSL Behring to Acquire Biotech Company Vitaeris
Jun 05, 2020
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
Jun 02, 2020
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
May 27, 2020
Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services
Apr 21, 2020
CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)
Mar 25, 2020
PharmaJet Announces Appointment of Pharmaceutical Executive Dr. Marie Mazur to the Board of Directors
Feb 24, 2020
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Feb 13, 2020
University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
Jan 21, 2020
Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity
Jan 09, 2020
Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference
Dec 09, 2019
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Nov 12, 2019
Influenza Vaccine Market to Reach $6.20 Bn, Globally, by 2026 at 5.9% CAGR: Allied Market Research
Oct 29, 2019
Global Vaccine Adjuvants Industry
Aug 30, 2019
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
Jul 01, 2019
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Jun 20, 2019
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting